Immunological effects of therapeutic immunoadsorption with respect to biocompatibility

Transfusion Science

Volumn 19, Issue SUPPL.1, 1998, Pages 9-23

  Kadar, Janos G ^a   Parusel, Marius ^b   Spaeth, Peter J ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Dept of Pediatric Surgery   (Germany)

^c Central Laboratory in Bern   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031904929     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Erdei A, Fust G, Gergely J: The role of C3 in the immune response. Immunol Today 1991; 12:332-337.
2. Spaeth PJ: Inhibitors of complement activation and of complement breakdown products. Plasma Ther Transf Technol 1987; 8:324-332.
3. Chenoweth DE: Anaphylatoxin formation in extracorporeal circuits. Complement 1986; 3:152-165.
4. Wegmuller E, Kazatchkine MD, Nydegger U: Complement activation during extracorporeal blood bypass. Plasma Ther Transf Technol 1983; 4:361-371.
5. Bhakdi S, Fassbender W, Hugo F et al: Relative inefficiency of terminal complement activation. J Immunol 1988; 141:3117-3122.
6. Kazatchkine MD, Carreno MP: Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials 1988; 9:30-35.
7. Cybulsky AV: Release of arachidonic acid by complement C5b-9 complex in glomerular epithelial cells. Am J Physiol 1991; 261:F427-436.
8. Johnson RJ: Complement activation by biomaterials, in Rock G, (ed.): Apheresis; Proceeding of the International Congress of World Apheresis Association, New York, Wiley-Liss Inc., 1990; pp. 507-512.
9. Morgan BP: Complement membrane attack on nucleated eels: resistance, recovery and non-lethal effects. Biochem J 1989; 264:1-14.
10. Salama A, Hugo F, Heinrich D et al: Deposition of terminal C5b-9 complement complexes on erythrocytes and leukocytes during cardiopulmonary bypass. N Engl J Med 1988; 318:408-414.
11. Stuard S, Carreno MP, Poignet JL, Albertazzi A, Haeffner-Cavaillon N: A major role for CD62P/CD1 5s interaction in leukocyte margination during hemodialysis. Kidney Int 1995; 48:93-102.
12. Lemke H, Schaefer R, Heidland A: Hypersensitivity reactions during hemodialysis: Role of complement fragments and ethylene oxid antibodies. Nephrology Dialysis and Transplantation 1990; 5:264-269.
13. Hakim RM, Fearon DT, Lazarus JM: Biocompatibility of dialysis membranes: effects of chronic complement activation. Kidney Int 1984; 26:194-200.
14. Carreno MP, Maillet F, Labarre D, Jozefowicz M, Kazatchkine MD: Specific antibodies enhance Sephadex-induced activation of the alternative complement pathway in human serum. Biomaterials 1988; 9:514-518.
15. von Sengbusch G, Bowry S, Vienken J: Focusing on membranes. Artif Organs 1993; 17:244-253.
16. Schindler R, Linnenweber S, Schultze M, Oppermann M, Dinarello CA, Shaldon S, Koch KM: Gene expression of interleukin-1 during hemodialysis. Kidney Int 1993; 43:712-721.
17. Parusel M: Investigations on the biocompatibility of LDL-apheresis. Thesis, Department Internal Medicine, University of Cologne, 1995.
18. Kadar JG, Borberg H: Biocompatibility of extracorporeal Immunoadsorption systems. Plasma Ther Transf Technol 1990; 11:223-239.
19. Kadar JG, Spaeth PJ, Gaczkowski A, Oette K, Borberg H: Biocompatibility studies on a clinically well tolerated extracorporeal system. Plasma Ther Transf Technol 1987; 8:307-318.
20. Nydegger U, Rieben R, Aeschbacher B: Biocompatibility of apheresis harness. Transfusion Science 1990; 11:43-54.
21. Stegmayr B, Tarnvik A: Complement activation in plasma exchange by single filtration and centrifugation and in cascade filtration. Blood Purif 1989; 7:10-15.
22. Ullrich H, Kadar JG, Waxenberger Y, et al.: Therapeutic thrombocytapheresis in patients with myeloproliferative disorders with the Fresenius AS 104 and COBE Spectra: Biocompatibility and safety. DGTI/ESFH Congress Würzburg (Abstract) 1991; pp. 20.
23. Kretschmer V, Sohngen D, Goddecke W, et al.: Biocompatibility and safety of cytapheresis. Infusionstherapie 1989; 16 (Suppl 2):10-20.
24. Stuard S, Carreno MP, Poignet JL, Albertazzi A, Haeffner Cavaillon N: A major role for CD62P/CD15s interaction in leukocyte margination during hemodialysis. Kidney Int 1995; 48:93-102.
25. Chignard M, Selak MA, Smith JB: Direct evidence for the existence of a neutrophil-derived platelet activator (neutrophilin). Proc Natl Acad Sci USA 1986; 83:8609-8613.
26. Evangelista V, Piccardoni P, White JG, de Gaetano G, Cerletti C: Cathepsin-G dependent platelet stimulation by activated polymorphonuclear leukocytes and its inhibition by antiproteinases: role of P-selectin mediated cell-adhesion. Blood 1993; 81:2947-2957.
27. Evangelista V, Piccardoni P, Maugeri N, de Gaetano G, Cerletti C: Inhibition by heparin of platelet activation induced by neutrophil derived cathepsin-G. Eur J Pharmacol 1992; 216:401-405.
28. Scharfstein J, Ferreira A, Gigli I, Nussenzweig V: Human C4 binding protein.I. Isolation and characterisation. J exp Med 1978; 148:207-222.
29. Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF: Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981; 67:223-228.
30. Motomura M, Fujishita S, Ohishi H, et al.: Complement in immunadsorption therapy. WAA 2nd Congress (Abstract), Ottawa Canada 1988; pp. 18.
31. Melchers F, Erdei A, Schulz T, Dierich MP: Growth control of activated, synchronised murine B cells by the C3d fragment of human complement. Nature 1985; 317(6034):264-267.
32. Szymanski IO: Ionised calcium during plateletpheresis. Transfusion 1978; 18:701-708.
33. Langone JJ, Das C, Bennett D, Terman DS: Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer. J Immunol 1057; 133:.
34. Nakanishi K, Zbar B, Borsos T, Glenn G: Serotherapy of primary rat mammary carcinoma: inhibition by ethylenedinitrilotetraacetic acid but not by [ethylenebis(oxyethylenenitrilo)]tetraacetic acid. Cancer Res 1986; 46:3886-3890.
35. Wallmark A, Grubb A, Freiburghaus C, et al.: Feasibility of extracorporeal on-line large-scale plasma adsorptions on protein A-sepharose columns in cancer patients. Artif Organs 1984; 8:72-81.
36. Kadar JG, Parusel M, Borberg H: Anticoagulation-dependent inhibition of in vitro complement activation by antiapo-B sepharose 4B CL. Infusionsther Transfusionsmed 1992; 19:237-240.
37. Bosch T, Schmidt B, Blumenstein M, Gurland HJ: Lipid Apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993; 17:640-652.
38. Videm V, Svennevig JL, Fosse E, Semb G, Osterud A, Mollnes TE: Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. J Thorac Cardiovasc Surg 1992; 103:806-813.
39. Fosse E, Moen O, Johnson E et al: Reduced complement and granulocyte activation with heparin-coated cardiopulmonary bypass. Ann Thorac Surg 1994; 58:472-477.
40. Moen O, Hogasen K, Fosse E, et al: Attenuation of changes in leukocyte surface markers and complement activation with heparin- coated cardiopulmonary bypass. Ann Thorac Surg 1997; 63:105-111.
41. Bichler J, Fritz H: Hirudin, a new therapeutic tool? Ann Hematol 1991; 63:67-76.
42. Goldstein JL, Brown MS: Familial hypercholesterolaemia. in Scriver CR, Beaudet AL, Sly WS, Valle D, (eds): The Metabolic Basis of Inherited Disease, 6th ed. New York, McGraw-Hill, 1989; pp.1215-1253.
43. Stoffel W, Demant T: Selective removal of apolipoprotein B-containing serum lipoproteins from blood plasma. Proc Natl Acad Sci USA 1981; 78:611-615.
44. Borberg H, Stoffel W, Oette K: The development of specific plasmaimmunadsorption. Plasma Ther Transf Technol 1983; 4:459-466.
45. Borberg H, Gaczkowski A, Hombach V, Oette K, Stoffel W: Regression of atherosclerosis in patients with familial hypercholesterolaemia under LDL-apheresis. Prog Clin Biol Res 1988; 255:317-326.
46. Waidner T, Franzen D, Voelker W et al.: The effect of LDL apheresis on progression of coronary artery disease in patients with familial hypercholesterolemia. Results of a multicenter LDL apheresis study. Clin Investig 1994; 72:858-863.
47. Gordon BR, Sloan BJ, Parker TS, Saal SD, Levine DM, Rubin AL: Humoral immune response following extracorporeal immunoadsorption therapy of patients with hypercholesterolemia. Transfusion 1990; 30:327-332.
48. Parusel M, Kadar JG, Borberg H: Anaphylatoxin generation and distribution during in vitro LDL apheresis. Infusionsther Transfusionsmed 1992; 19:245-248.
49. Parusel M, Kadar JG, Spaeth PJ, et al: Complement activation of the antiApo B Sepharose-4B-Column during uneventful LDL-apheresis sessions depends exclusively on the column age. Transfusion Medicine (Abstract 1993; 3 (Suppl 1):33.
50. Belak M, Widder RA, Brunner R, Borberg H, Haupt WF: Immunoadsorption with protein A sepharose or silica. Lancet (Letter comment) 1994; 343:792-793.
51. Solomon A, Fahey JL: Plasmapheresis therapy in macroglobulinaemia. Ann Intern Med 1963; 58:789-792.
52. Pinching AJ, Peters DK, Newsom-Davis J: Remission of myasthenia gravis following plasma exchange. Lancet 1976; ii:1373-1376.
53. Keller AJ, Urbaniak SJ: Intensive plasma exchange on the cell separator. Effects on serum immunoglobulins and complement components. Br J Hematol 1978; 531-534.
54. von Zeipel G, Hanson HS, von Stedingk LV: Purification from euglobulin of the first component (Cl) of complement and its subcomponents by heparin-Sepharose chromatography. Acta Pathol Microbiol Scand 1977; 85:123-130.
55. Weiler JM, Yurt RW, Fearon DT, Austen KF: Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin. J Exp Med 1978; 147:409-421.
56. Baker PJ, Lint TF, McLeod BC, Behnrends CL, Gewurz H: Studies on the inhibiton of C56-induced lysis (reactive lysis) Vl. Modulation of C56-induced lysis by polyanions and polycations. J Immunol 1975; 114:554-558.
57. Spycher MO, Nydegger U: Control of the immune complex complement interaction by protein H of the alternative complement pathway and the natural inhibitor heparin. European Journal of Immunology 1984; 14:276-279.
58. Loos M, Volanakis JE, Stroud RM: Mode of interaction of different polyanions with the first (Cl, Cl), the second (C2) and the fourth (C4) component of complement-111. Inhibition of C4 and C2 binding site(s) on C1s by polyanions. Immunochemistry 1976; 13:789-791.
59. Maillet F, Petitou M, Choay J, Kazatchkine MD: Structure function relationships in the inhibitory effect of heparin on complement activation: Independency of the anticoagulatory and anti- complementary sites on the heparin molecule. Mol Immunol 1983; 20:917-923
60. Tschopp J, Masson D, Schäfer S, Peitsch M, Preissner KT: The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, C9 and perforin from cytolytic T cells and inhibits their Iytic activities. Biochemistry 1988; 27:4103-4109.
61. Wesolowski J, Ault K, Houghton R, Parkman R: Heparin inhibition of antibody dependent complement mediated lysis. Experimental Hematology 1984; 12:700-705.
62. Caughmann GB, Boackle RJ, Vesely J: A postulated mechanism for heparins potentiation of C1-inhibitor function. Mol Immunol 1982; 19:287-295.
63. Boackle RJ, Caughmann GB, Vesely J, Medgyesi G, Fudenberg HH: Potentiation of Factor H by heparin: a rate limiting mechanism for inhibition of the alternative complement pathway. Mol-Immunology 1983; 20:1157-1164.
64. Meri S, Pangburn MK: Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on Factor H. Proc Natl Acad Sci USA 1990; 87:3982-3986.
65. Fiedel BA, Rent R, Myhrman R, Gewurz H: Complement activation by interaction of polyanions and polycations II. Precipitation and role of IgG, C1q and C1-lnh during Heparin-protamine induced consumption of complement. Immunology 1976; 30:161-169.
66. Jepsen HH, Ekre HPT, Svehag SE: Interaction of complement solubilised immune complexes (IC) with CR1 receptors on human erythrocytes. Polysulfated compounds inhibit IC binding and induce IC-release from CR1. Int J Immunopharmacol 1987; 9:587-595.